Tier 3 — preclinical
Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules
Angewandte Chemie International Edition
2017
56(4):1007-1011
Bibliography
- PubMed
- PMID 27990725
- Funding
- Funding indexed for this publication includes National Institute on Aging support.
- Competing interests
- No competing-interest statement was identified in the accessible publication record.
Study snapshot
| Design | Medicinal-chemistry, biochemical activation and X-ray crystallography study. |
|---|---|
| Model | Purified SIRT6 enzyme, peptide/nucleosome substrates and structural complexes. |
| Sample | Not applicable; biochemical and structural experiments. |
| Intervention | Pyrrolo[1,2-a]quinoxaline SIRT6-activating compounds. |
| Duration | Not applicable. |
| Endpoints | SIRT6 deacetylase activation; compound binding; substrate dependence; crystal structure and binding-site interactions |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- SIRT6 Therapeutics: Gene Therapy, Activators, Inhibitors & PeptidesSIRT6 can be targeted with gene therapy, allosteric activators, inhibitors and experimental peptides. See AAV research, MDL-800, UBCS039, forvisirvat and why inhibition...Read analysis
- SIRT6 Activator: Natural Compounds, Synthetic Drugs & Human EvidenceSIRT6 activators include natural compounds such as cyanidin and fucoidan, synthetic research molecules such as MDL-800, and clinical-stage forvisirvat. Here is what...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
